Threshold Pharmaceuticals Selectively Targets Tumor Cells in Cancer Therapeutics
Threshold Pharmaceuticals takes advantage of the differences in metabolic activity between cancerous and normal, healthy biological tissue.
Featured Articles
BMEYE’s Heart Monitoring Technology May Set A New Standard In Patient Care
During an average life span of 70 years, the human heart will pump more than 400 million litres of blood.
Mystic Pharmaceuticals’ Intranasal Technology Introduces Solutions In Drug Delivery
Delivery of drugs and vaccines via the nose offer many compelling advantages including reduced nausea and toxicity and rapid onset.
Icagen and Pfizer Form Three Way Collaboration with Yale To Explore Chronic Pain Remedies
Chronic pain and epilepsy are debilitating disorders that affect millions of individuals in the US and throughout the world.
Wound Management Technologies Addresses Multi Billion Dollar Wound Care Market With CellerateRX
Wound Management’s FDA approved product has become a primary treatment for all types of wounds and sparked interest in the investment community.
The Long and Short of CerviLenz Prenatal Technology
Cervilenz has developed an innovative low cost, single use medical device that accurately measures a pregnant woman’s cervical length, which is the best indicator of preterm birth risk.
InTUUN’s Cooperative Health Record Integration Puts the Patient First
In this age where more and more modes of communication are being created, it is natural to find innovative ways to connect health professionals and patients.
Provectus Pharmaceuticals Uses Old Drug To Actualize Novel Therapeutics for Cancer and Skin Disorders
Provectus Pharmaceuticals develops a powerful drug pipeline with minimal side effects, including a cancer drug that targets cancer tissue, as well as…
Cynvenio Biosystems Selected as 2011 FiReStarter Company
Strategic News Service recently announced that Cynvenio Biosystems has been selected as a 2011 FiReStarter company, to be featured at its annual Future in Review technology conference.
Biovista Partners With Novartis to Enhance Drug Repurposing Efforts
Biovista announced recently that it has entered into a research collaboration agreement with Novartis.